Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025
Telomir Pharmaceuticals (NASDAQ: TELO) reported new preclinical data showing its lead drug Telomir-1 killed HL60 leukemia cells in vitro. Director Dr. Craig Eagle resigned from the board, effective November 14, with no dispute cited. TELO stock jumped 8% pre-market but recently traded at $1.39, down 3% from the prior close. Shares remain down about two-thirds year-to-date.
